HEPARIN SODIUM AND DEXTROSE 5% INJ USP 5 G / 100 ML
DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 4000 UNIT / 100 ML · DIN 01913255 · BAXTER CORPORATION
Health Canada status: CANCELLED POST MARKET
What is HEPARIN SODIUM AND DEXTROSE 5% INJ USP?
HEPARIN SODIUM AND DEXTROSE 5% INJ USP 5 G / 100 ML contains DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 4000 UNIT / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 01913255, held by BAXTER CORPORATION, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 01-Feb-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01913255 |
|---|---|
| Brand name | HEPARIN SODIUM AND DEXTROSE 5% INJ USP |
| Generic / active ingredient | DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 4000 UNIT / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 5 G / 100 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B01AB51 HEPARIN, COMBINATIONS |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Feb-2011 |
What can be used instead?
Other Canadian products sharing ATC code B01AB51 HEPARIN, COMBINATIONS. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPARIN SOD AND 0.9% SOD CHLORIDE INJ | 2 UNIT | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00828750 |
| HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ | 4000 UNIT / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02209713 |
| HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02209721 |
| HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01935941 |
| HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02008181 |
| HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 01900757 |
| HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION | 430 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | DORMANT | DIN 01935933 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.